BT-001 Diabetes Digital Therapeutic Device
De Novo DEN220058
Active
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA De NovoDENG | NumberDEN220058 | Date7 Jul 2023 | StatusActive |
Official records
- FDA De Novo database DEN220058
From the FDA record
- Received by the FDA
- 21 Sep 2022
- FDA decision
- 7 Jul 2023
- FDA review time
- 289 days from receipt to decision
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA De Novo Active
Specification
- Full name
- Bt-001
- De Novo Number
- FDA product code
- QXC
- Device class
- Class II
- Regulation
- 21 CFR Part 880.5735
- Advisory committee
- General Hospital
- FDA decision
- DENG De Novo granted
Overview
AI-generated summary, 21 Sep 2026
The Bt-001 Diabetes Digital Therapeutic Device is a prescription-only digital therapeutic device that provides cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. It is intended to be used adjunctively with standard of care. The device is classified as a class 2 device with the regulation number 880.5735.
The Bt-001 is supplied as a single device and is indicated for use in patients with type 2 diabetes. It is authorized by the FDA with a 510K clearance. The device is used in a general hospital setting and has a product code of QXC. The device is for single use and is not specified as MRI safe or sterile in the provided data.
Devices cleared under DEN220058
Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.
| UDI-DI | Size and differences | |||
|---|---|---|---|---|
| AspyreRx ma.1.0.0 | ma.1.0.0 | 00860011146704 | — | On the market |